RETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows

Rhea-AI Summary

Shuttle Pharmaceuticals (NASDAQ:SHPH) on March 27, 2026 announced a major upgrade to its molecule.ai platform, adding generative and predictive models plus a preview of an autonomous, multi-agent AI system for scientific workflows.

The release emphasizes multi-step reasoning, multimodal data ingestion, and orchestration to accelerate therapeutic discovery and reduce manual research effort.

News Market Reaction – SHPH

-22.87% 4.4x vol

37 alerts

-22.87% News Effect

-44.8% Trough in 6 hr 43 min

-$1M Valuation Impact

$4.81M Market Cap

4.4x Rel. Volume

On the day this news was published, SHPH declined 22.87%, reflecting a significant negative market reaction. Argus tracked a trough of -44.8% from its starting point during tracking. Our momentum scanner triggered 37 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $4.81M at that time. Trading volume was very high at 4.4x the daily average, suggesting heavy selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Gaithersburg, Maryland--(Newsfile Corp. - March 27, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), today announced a major advancement to its molecule.ai platform, significantly expanding its capabilities in therapeutic discovery and positioning the Company at the forefront of AI-driven drug development.

The latest release introduces new models that enable users to more effectively evaluate, prioritize, and advance therapeutic candidates. By integrating enhanced predictive and generative capabilities into a unified platform, Shuttle Pharma is accelerating the transition from fragmented data analysis toward a scalable, end-to-end solution for therapeutic development.

This update marks a critical evolution for AI-driven drug discovery: from standalone model outputs to a more sophisticated reasoning system. The platform can now identify and prioritize relationships between genes and disease pathways and predict compound interactions with specific biological targets. Combined with existing molecular prediction tools, molecule.ai delivers a more connected and efficient framework for evaluating therapeutic opportunities—driving faster, higher-confidence decision-making earlier in the discovery lifecycle.

In addition, the Company unveiled a preview of its next-generation autonomous AI agent system, built on top of frontier AI models. This system is designed to move beyond traditional single-step predictions by enabling multi-step reasoning and multi-agent orchestration across complex scientific workflows. The agents will be capable of ingesting multimodal data, leveraging integrated tools, and executing discrete research tasks—dramatically reducing manual effort and increasing throughput for research teams.

"This release represents a meaningful step toward fully autonomous therapeutic discovery," said Chris Cooper, Chief Executive Officer of Shuttle Pharma. "We are not just improving model performance—we are redefining how drug development workflows are executed. By integrating reasoning, prediction, and automation into a single platform, molecule.ai has the potential to materially reduce timelines, lower costs, and increase the probability of success across the development pipeline. We believe this positions Shuttle Pharma to play a leading role in the next generation of AI-powered biopharma innovation."

As Shuttle Pharma continues to expand molecule.ai's capabilities, the Company remains focused on building a scalable platform that can unlock new therapeutic opportunities, improve development efficiency, and create long-term value for shareholders.

About Shuttle Pharma

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) owns a pharmaceutical software artificial intelligence ("AI") driven platform for molecular discovery and early-stage drug development. By combining modern AI techniques with structured scientific workflows, the Molecule.ai platform helps researchers explore the chemical space more efficiently, evaluate molecular ideas with greater clarity and make more informed decisions during the earliest stages of drug development.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements concerning the development and future capabilities of the Molecule.ai platform. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including our ability to realize the anticipated benefits from the Molecule.ai platform, risks related to the acquisition and retention of future customers and our ability to generate revenue, our ability to fund our future operations, risks regarding our intellectual property, risks regarding our ability to maintain the listing of our common stock on Nasdaq, as well as other factors discussed in Shuttle Pharma's SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharma disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Shuttle Pharmaceuticals
Chris Cooper
Chief Executive Officer
info@shuttlepharma.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290201

FAQ

What did Shuttle Pharmaceuticals (SHPH) announce about molecule.ai on March 27, 2026?

Shuttle announced upgraded predictive and generative models plus an autonomous multi-agent AI preview. According to the company, these enhancements enable multi-step reasoning, multimodal data ingestion, and orchestration across scientific workflows to accelerate therapeutic discovery and decision-making.

How will the new autonomous AI agents in molecule.ai affect research workflows at SHPH?

The agents aim to reduce manual work and increase throughput for research teams. According to the company, agents will ingest multimodal data, use integrated tools, and execute discrete tasks to streamline complex scientific workflows and speed early-stage evaluation.

Does the molecule.ai update enable predictive biology features for Shuttle Pharmaceuticals (SHPH)?

Yes — the update improves predictive biology by identifying gene-disease relationships and compound-target interactions. According to the company, these capabilities integrate with existing molecular prediction tools to prioritize therapeutic candidates earlier in discovery.

Will the molecule.ai enhancements materially change Shuttle Pharmaceuticals' (SHPH) drug discovery timeline?

The company says the platform could materially shorten timelines and lower costs in discovery. According to the company, integrated reasoning, prediction, and automation are intended to increase decision confidence and speed earlier pipeline decisions.

Is Shuttle Pharmaceuticals (SHPH) offering the autonomous agent system now or as a preview?

Shuttle provided a preview of its next-generation autonomous agent system rather than a full release. According to the company, the preview showcases multi-agent orchestration and frontier model integration as part of ongoing platform development.

How does Shuttle Pharmaceuticals (SHPH) describe the strategic aim of the molecule.ai upgrade?

The company frames the upgrade as a step toward fully autonomous therapeutic discovery and a scalable end-to-end platform. According to the company, the goal is to unlock new opportunities, improve development efficiency, and create long-term shareholder value.